Targeted microbubbles carrying lipid-oil-nanodroplets for ultrasound-triggered delivery of the hydrophobic drug, combretastatin A4

• Published in: Nanomedicine Vol. 36; p. 102401
• Main Authors: Charalambous, Antonia, Mico, Victoria, McVeigh, Laura E., Marston, Gemma, Ingram, Nicola, Volpato, Milène, Peyman, Sally A., McLaughlan, James R., Wierzbicki, Antonia, Loadman, Paul M., Bushby, Richard J., Markham, Alexander F., Evans, Stephen D., Coletta, P. Louise
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2021
• Subjects: Animals; Cell Line, Tumor; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - metabolism; Colorectal Neoplasms - pathology; Combretastatin A4; Humans; Hydrophobic and Hydrophilic Interactions; Lipid-Oil-Nanodroplets (LONDs); Lipids - chemistry; Lipids - pharmacokinetics; Lipids - pharmacology; Mice; Mice, Inbred BALB C; Mice, Nude; Microbubbles; Nanostructures - chemistry; Nanostructures - therapeutic use; Stilbenes - chemistry; Stilbenes - pharmacokinetics; Stilbenes - pharmacology; Targeting; Ultrasonography; Ultrasound trigger; Xenograft Model Antitumor Assays; LOD; VEGFR2; Combretastatin A4; Targeting; Tx; CA4P; EPR; Ultrasound trigger; i.p; ICAM-1; CA4G; LONDs; i.v; Lipid-Oil-Nanodroplets (LONDs); VDA; CRC; CA4; TGI; Microbubbles; CEPs; US; 5-FU; MBs

The hydrophobicity of a drug can be a major challenge in its development and prevents the clinical translation of highly potent anti-cancer agents. We have used a lipid-based nanoemulsion termed Lipid-Oil-Nanodroplets (LONDs) for the encapsulation and in vivo delivery of the poorly bioavailable comb...